CA2777749C - Therapeutic peptides comprising a disubstituted beta-amino acid for treating microbial infections or tumours - Google Patents
Therapeutic peptides comprising a disubstituted beta-amino acid for treating microbial infections or tumours Download PDFInfo
- Publication number
- CA2777749C CA2777749C CA2777749A CA2777749A CA2777749C CA 2777749 C CA2777749 C CA 2777749C CA 2777749 A CA2777749 A CA 2777749A CA 2777749 A CA2777749 A CA 2777749A CA 2777749 C CA2777749 C CA 2777749C
- Authority
- CA
- Canada
- Prior art keywords
- amino acid
- peptide
- peptidomimetic
- group
- acid derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0919194.1 | 2009-11-02 | ||
| GBGB0919194.1A GB0919194D0 (en) | 2009-11-02 | 2009-11-02 | Compounds |
| PCT/GB2010/002024 WO2011051692A1 (en) | 2009-11-02 | 2010-11-02 | Therapeutic peptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2777749A1 CA2777749A1 (en) | 2011-05-05 |
| CA2777749C true CA2777749C (en) | 2019-08-06 |
Family
ID=41435032
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2777749A Active CA2777749C (en) | 2009-11-02 | 2010-11-02 | Therapeutic peptides comprising a disubstituted beta-amino acid for treating microbial infections or tumours |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8809280B2 (https=) |
| EP (1) | EP2496596B1 (https=) |
| JP (1) | JP5810090B2 (https=) |
| KR (1) | KR101730680B1 (https=) |
| CN (1) | CN102762586B (https=) |
| AU (1) | AU2010311186B2 (https=) |
| CA (1) | CA2777749C (https=) |
| DK (1) | DK2496596T3 (https=) |
| ES (1) | ES2621188T3 (https=) |
| GB (1) | GB0919194D0 (https=) |
| NZ (1) | NZ599791A (https=) |
| PL (1) | PL2496596T3 (https=) |
| RU (2) | RU2548905C2 (https=) |
| WO (1) | WO2011051692A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202446781A (zh) | 2011-12-28 | 2024-12-01 | 日商中外製藥股份有限公司 | 胜肽化合物之製造方法 |
| EP4166664A1 (en) | 2015-03-13 | 2023-04-19 | Chugai Seiyaku Kabushiki Kaisha | Modified aminoacyl-trna synthetase and use thereof |
| GB201601868D0 (en) | 2016-02-02 | 2016-03-16 | Lytix Biopharma As | Methods |
| EP3444264A4 (en) * | 2016-04-14 | 2020-03-18 | TAO Health Life Pharma Co., Ltd. | Peptide for inhibiting binding of amylospheroids (aspd), and evaluation and screening method |
| JP7187323B2 (ja) | 2017-01-31 | 2022-12-12 | 中外製薬株式会社 | 無細胞翻訳系におけるペプチドの合成方法 |
| GB201705255D0 (en) * | 2017-03-31 | 2017-05-17 | Univ I Tromsø - Norges Arktiske Univ | Bioactive cyclic compounds |
| WO2018188761A1 (en) | 2017-04-13 | 2018-10-18 | Lytix Biopharma As | Method of reducing population size of tregs and/or mdscs |
| KR20250007021A (ko) | 2017-06-09 | 2025-01-13 | 추가이 세이야쿠 가부시키가이샤 | N-치환 아미노산을 포함하는 펩타이드의 합성 방법 |
| WO2019117274A1 (ja) | 2017-12-15 | 2019-06-20 | 中外製薬株式会社 | ペプチドの製造方法、及び塩基の処理方法 |
| EP3878836B1 (en) | 2018-11-07 | 2025-07-23 | Chugai Seiyaku Kabushiki Kaisha | O-substituted serine derivative production method |
| WO2020111238A1 (ja) | 2018-11-30 | 2020-06-04 | 中外製薬株式会社 | ペプチド化合物、またはアミド化合物の脱保護法および固相反応における脱樹脂方法、並びにペプチド化合物の製造方法 |
| EP3939962A4 (en) | 2019-03-15 | 2022-12-28 | Chugai Seiyaku Kabushiki Kaisha | PROCESS FOR PREPARING AN AROMATIC AMINO ACID DERIVATIVE |
| CN110294793B (zh) * | 2019-06-24 | 2023-10-27 | 合肥科生景肽生物科技有限公司 | Sumo荧光探针及其制备方法 |
| BR112022007535A2 (pt) | 2019-11-07 | 2022-07-12 | Chugai Pharmaceutical Co Ltd | Composto peptídico cíclico tendo ação inibitória de kras |
| CN114790151B (zh) * | 2022-02-14 | 2023-03-31 | 湖南省湘中制药有限公司 | 一种2-氰基-2-丙戊酸甲酯的复合催化制备方法 |
| WO2024133588A1 (en) | 2022-12-20 | 2024-06-27 | Lytix Biopharma As | Compositions comprising an oncolytic peptide and chitosan |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4342705A (en) | 1979-11-23 | 1982-08-03 | Monsanto Company | Methylene thioethers |
| AU565221B2 (en) | 1982-06-03 | 1987-09-10 | Montedison S.P.A. | 2-(1,2,4-triazol-1-yl) propanone derivatives |
| IT1161927B (it) | 1983-03-31 | 1987-03-18 | Montedison Spa | Furano-derivati ad attivita' fungicida |
| DK523288A (da) | 1987-10-06 | 1989-04-07 | Hoffmann La Roche | Aminosyrederivater |
| CA1328333C (en) | 1988-03-04 | 1994-04-05 | Quirico Branca | Amino acid derivatives |
| US5593967A (en) | 1990-08-31 | 1997-01-14 | Warner-Lambert Company | Cholecystokinin antagonists, their preparation and therapeutic use |
| NZ239595A (en) | 1990-08-31 | 1994-06-27 | Warner Lambert Co | Cholecystokinin antagonistic compounds ; pharmaceutical compositions and use thereof |
| US5387671A (en) | 1990-12-27 | 1995-02-07 | Abbott Laboratories | Hexa- and heptapeptide anaphylatoxin-receptor ligands |
| US5885782A (en) | 1994-09-13 | 1999-03-23 | Nce Pharmaceuticals, Inc. | Synthetic antibiotics |
| US6323227B1 (en) | 1996-01-02 | 2001-11-27 | Aventis Pharmaceuticals Products Inc. | Substituted N-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides |
| US6080767A (en) | 1996-01-02 | 2000-06-27 | Aventis Pharmaceuticals Products Inc. | Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides |
| AU723338B2 (en) | 1996-01-02 | 2000-08-24 | Aventis Pharmaceuticals Inc. | Substituted n-{(aminoiminomethyl or aminomethyl)phenyl}propyl amides |
| JP3734907B2 (ja) | 1996-12-19 | 2006-01-11 | 富士写真フイルム株式会社 | 現像処理方法 |
| DE102006018080A1 (de) * | 2006-04-13 | 2007-10-18 | Aicuris Gmbh & Co. Kg | Lysobactinamide |
| AU2007272272B2 (en) * | 2006-07-10 | 2012-04-12 | Pba3 Biomed Gmbh | Antimicrobial peptides |
| GB0724951D0 (en) * | 2007-12-20 | 2008-01-30 | Lytix Biopharma As | Compounds |
| DE602008002706D1 (de) * | 2008-03-18 | 2010-11-04 | Univ Dresden Tech | Modulares Gerüst zur Gestaltung von spezifischen Molekülen zur Verwendung als Pepitmimetika und Hemmer für die Proteininteraktion |
-
2009
- 2009-11-02 GB GBGB0919194.1A patent/GB0919194D0/en not_active Ceased
-
2010
- 2010-11-02 CA CA2777749A patent/CA2777749C/en active Active
- 2010-11-02 JP JP2012535924A patent/JP5810090B2/ja active Active
- 2010-11-02 WO PCT/GB2010/002024 patent/WO2011051692A1/en not_active Ceased
- 2010-11-02 CN CN201080049560.6A patent/CN102762586B/zh active Active
- 2010-11-02 EP EP10784830.1A patent/EP2496596B1/en active Active
- 2010-11-02 PL PL10784830T patent/PL2496596T3/pl unknown
- 2010-11-02 AU AU2010311186A patent/AU2010311186B2/en active Active
- 2010-11-02 US US13/505,625 patent/US8809280B2/en active Active
- 2010-11-02 ES ES10784830.1T patent/ES2621188T3/es active Active
- 2010-11-02 NZ NZ599791A patent/NZ599791A/en unknown
- 2010-11-02 DK DK10784830.1T patent/DK2496596T3/en active
- 2010-11-02 RU RU2012121264/04A patent/RU2548905C2/ru active
- 2010-11-02 KR KR1020127014266A patent/KR101730680B1/ko active Active
- 2010-11-02 RU RU2015111706A patent/RU2676713C2/ru active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010311186B2 (en) | 2015-09-24 |
| US20130035296A1 (en) | 2013-02-07 |
| NZ599791A (en) | 2014-10-31 |
| JP5810090B2 (ja) | 2015-11-11 |
| CN102762586B (zh) | 2016-10-05 |
| US8809280B2 (en) | 2014-08-19 |
| DK2496596T3 (en) | 2017-04-03 |
| ES2621188T3 (es) | 2017-07-03 |
| AU2010311186A1 (en) | 2012-05-31 |
| EP2496596A1 (en) | 2012-09-12 |
| KR20120104986A (ko) | 2012-09-24 |
| JP2013509389A (ja) | 2013-03-14 |
| EP2496596B1 (en) | 2017-01-11 |
| CA2777749A1 (en) | 2011-05-05 |
| RU2012121264A (ru) | 2013-12-10 |
| BR112012010333A2 (pt) | 2016-03-29 |
| RU2015111706A3 (https=) | 2018-10-29 |
| PL2496596T3 (pl) | 2017-08-31 |
| WO2011051692A1 (en) | 2011-05-05 |
| CN102762586A (zh) | 2012-10-31 |
| RU2548905C2 (ru) | 2015-04-20 |
| RU2015111706A (ru) | 2015-11-10 |
| RU2676713C2 (ru) | 2019-01-10 |
| GB0919194D0 (en) | 2009-12-16 |
| KR101730680B1 (ko) | 2017-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2777749C (en) | Therapeutic peptides comprising a disubstituted beta-amino acid for treating microbial infections or tumours | |
| EP1263471B1 (en) | Antimicrobial compounds and formulations | |
| CA3188410A1 (en) | Conjugated hepcidin mimetics | |
| US12115224B2 (en) | Polypeptide conjugates for intracellular delivery of stapled peptides | |
| US20210169966A1 (en) | Peptidyl inhibitors of calcineurin-nfat interaction | |
| SK286581B6 (sk) | Deriváty dolastatinu 15, farmaceutický prípravok s ich obsahom a ich použitie | |
| JP2016065018A (ja) | Ｃｘｃｒ７結合剤およびｃｘｃｒ７結合剤を含有する医薬組成物 | |
| JP6701083B2 (ja) | 抗リンパ腫ペプチド | |
| Chowdhary et al. | Synthesis, characterization, and antimicrobial activity of ultra-short cationic β-peptides | |
| Grogg et al. | Cell penetration, herbicidal activity, and in‐vivo‐toxicity of oligo‐arginine derivatives and of novel guanidinium‐rich compounds derived from the biopolymer cyanophycin | |
| JP6468562B2 (ja) | プロテアソーム阻害性化合物 | |
| CA2883531A1 (en) | Stable peptide-based furin inhibitors | |
| EP3328877B1 (en) | Peptoid | |
| WO2009081151A2 (en) | Methods of peptide modification | |
| US6153585A (en) | Arylsulfonanilide derivatives | |
| BR112012010333B1 (pt) | Peptídeo ou derivado de aminoácido, seu uso, bem como formulação que os compreendem | |
| JPWO2012118124A1 (ja) | 新規ケモカイン受容体拮抗剤 | |
| EP4267251A1 (en) | Cyclic peptides and uses thereof | |
| WO2025080942A1 (en) | Proteasome inhibitors and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20130212 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD Year of fee payment: 14 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241028 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241028 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241028 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - STANDARD Year of fee payment: 15 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251022 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251022 |